ArriVent: Bing Yao’s next start-up to test a ‘reverse model’ of cross-border in-licensing strategies

Putting a twist on the cross-border companies that have brought drugs from the West to the Greater China market, newly launched ArriVent is going in the other direction: sourcing innovative products from China and developing them globally.

CEO Bing Yao, who this year led Viela Bio Inc. (NASDAQ:VIE) through its $3 billion-plus acquisition by Horizon Therapeutics plc (NASDAQ:HZNP), told BioCentury that ArriVent BioPharma Inc. will use a “reverse model” compared with other cross-border companies. The start-up said it will source programs from China and “other emerging biotech hubs.”...